Eton Pharmaceuticals Inc (ETON) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: $89.4M

ETON ranks #3440 out of 37503 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ETON is a top-conviction position for Opaleye Management Inc. — at 9.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Opaleye Management Inc. has added to its ETON position for two straight quarters, increasing it by $55.2M to reach $103.5M today.

Connor, Clark & Lunn Investment Management Ltd. has trimmed its ETON position for two straight quarters, cutting it by $819.0K while still holding $476.0K.

ETON is down 0% today, but institutions show net buying of $89.4M this quarter — a divergence between today's price move and the underlying institutional flow.

ETON posted net income of $12.7M over the trailing twelve months.

• Profitable — net income of $12.7M over the trailing twelve months
• Revenue grew 81.5% year over year
• Net income improved year over year, from -$4.1M to $12.7M
• Generated $10.5M in positive operating cash flow
• Current ratio of 1.57x — enough short-term assets to cover short-term liabilities
• Liabilities run 2.52x equity — a highly leveraged balance sheet worth noting